BTK and B-cell chronic lymphocytic leukemia: It is increasingly clear that in addition to their direct effects on B cells, both BTK inhibitors also directly impact the phenotype and function of many other cell subsets of the immune system, which contribute to their high efficacy as well as adverse effects observed in CLL and MCL patients.